{
  "data": [
    {
      "id": "obs-inc-2025",
      "entity_type": "epidemiology",
      "entity_id": "inc-2025",
      "variable": "casos",
      "value": 22435,
      "unit": "pacientes incidentes",
      "year": 2025,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-redecan-2025",
      "formula": "18.281 + 4.154",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "obs-sns-2024",
      "entity_type": "SNS",
      "entity_id": "recetas-2024",
      "variable": "gasto",
      "value": 13865000000,
      "unit": "EUR",
      "year": 2024,
      "territory": "España",
      "status": "observado",
      "source_document_id": "doc-farmacia-2024",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "obs-market-2024",
      "entity_type": "bladder-cancer",
      "entity_id": "spain-2024",
      "variable": "gasto farmacológico atribuible",
      "value": null,
      "unit": "EUR",
      "year": 2024,
      "territory": "España",
      "status": "no_disponible",
      "source_document_id": "doc-redecan-2025",
      "formula": "No publicado por indicación; faltan pacientes, consumo y precios netos",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "blarwe-stage",
      "entity_type": "blarwe",
      "entity_id": "cohort-3397",
      "variable": "NMIBC",
      "value": 79.2,
      "unit": "%",
      "year": 2018,
      "territory": "21 hospitales España",
      "status": "observado",
      "source_document_id": "doc-blarwe",
      "formula": "2692/3397; incluye recurrencias",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "blarwe-mibc",
      "entity_type": "blarwe",
      "entity_id": "cohort-3397",
      "variable": "MIBC",
      "value": 17.7,
      "unit": "%",
      "year": 2018,
      "territory": "21 hospitales España",
      "status": "observado",
      "source_document_id": "doc-blarwe",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "blarwe-met",
      "entity_type": "blarwe",
      "entity_id": "cohort-3397",
      "variable": "metastásico",
      "value": 3,
      "unit": "%",
      "year": 2018,
      "territory": "21 hospitales España",
      "status": "observado",
      "source_document_id": "doc-blarwe",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "blarwe-bcg",
      "entity_type": "blarwe",
      "entity_id": "hr-nmibc-294",
      "variable": "BCG en nuevos alto/muy alto riesgo",
      "value": 64.9,
      "unit": "%",
      "year": 2018,
      "territory": "cohorte 2",
      "status": "observado",
      "source_document_id": "doc-blarwe",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "blarwe-mito",
      "entity_type": "blarwe",
      "entity_id": "hr-nmibc-294",
      "variable": "mitomicina inducción post TURBT",
      "value": 12.6,
      "unit": "%",
      "year": 2018,
      "territory": "cohorte 2",
      "status": "observado",
      "source_document_id": "doc-blarwe",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "puente-1l",
      "entity_type": "puente-2025",
      "entity_id": "advanced-829",
      "variable": "tratamiento sistémico 1L",
      "value": 84.7,
      "unit": "%",
      "year": 2015,
      "territory": "9 hospitales; periodo 2015-2020",
      "status": "observado",
      "source_document_id": "doc-puente",
      "formula": null,
      "consulted_at": "2026-11-06"
    },
    {
      "id": "puente-2l",
      "entity_type": "puente-2025",
      "entity_id": "advanced-1l-702",
      "variable": "segunda línea",
      "value": 46.9,
      "unit": "%",
      "year": 2015,
      "territory": "9 hospitales; periodo 2015-2020",
      "status": "observado",
      "source_document_id": "doc-puente",
      "formula": "329/702",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "puente-3l",
      "entity_type": "puente-2025",
      "entity_id": "advanced-1l-702",
      "variable": "tercera línea",
      "value": 16.6,
      "unit": "%",
      "year": 2015,
      "territory": "9 hospitales; periodo 2015-2020",
      "status": "observado",
      "source_document_id": "doc-puente",
      "formula": "116/702",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "proc-awarded",
      "entity_type": "procurement",
      "entity_id": "selected-2024",
      "variable": "adjudicado seleccionado",
      "value": 4370602,
      "unit": "EUR sin IVA",
      "year": 2024,
      "territory": "País Vasco y La Paz",
      "status": "observado",
      "source_document_id": "doc-proc-awarded",
      "formula": "1.586.659+1.838.940+945.003; no sumar al mercado",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "proc-executed",
      "entity_type": "procurement",
      "entity_id": "selected-2024",
      "variable": "ejecutado documentado",
      "value": null,
      "unit": "EUR",
      "year": 2024,
      "territory": "País Vasco y La Paz",
      "status": "no_disponible",
      "source_document_id": "doc-proc-executed",
      "formula": "No hay certificaciones de ejecución ni fracción vejiga",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "hosp-cost-2025",
      "entity_type": "SNS-general",
      "entity_id": "hosp-2025",
      "variable": "Coste real consumo medicamentos hospitalarios",
      "value": 11336197908,
      "unit": "EUR",
      "year": 2025,
      "territory": "SNS red pública; CCAA, Ceuta y Melilla",
      "status": "observado",
      "source_document_id": "doc-sanidad-hosp-2025",
      "formula": "Tabla Coste real consumo, acumulado interanual; no vejiga, no sumar al modelo",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "hosp-cost-2024",
      "entity_type": "SNS-general",
      "entity_id": "hosp-2024",
      "variable": "Coste real consumo medicamentos hospitalarios",
      "value": 10536241377,
      "unit": "EUR",
      "year": 2024,
      "territory": "SNS red pública; CCAA, Ceuta y Melilla",
      "status": "observado",
      "source_document_id": "doc-sanidad-hosp-2025",
      "formula": "Comparador misma tabla, no vejiga, no sumar al modelo",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "hosp-envases-2025",
      "entity_type": "SNS-general",
      "entity_id": "hosp-2025",
      "variable": "Envases consumidos",
      "value": 92149474,
      "unit": "envases",
      "year": 2025,
      "territory": "SNS red pública; todos medicamentos",
      "status": "observado",
      "source_document_id": "doc-sanidad-hosp-2025",
      "formula": "Tabla envases acumulado; excluye situaciones especiales en Galicia",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "avel-eligible",
      "entity_type": "rwe",
      "entity_id": "avebladder-419",
      "variable": "Elegibles respuesta/estabilidad entre recibió quimioterapia",
      "value": 62,
      "unit": "%",
      "year": 2023,
      "territory": "14 centros norte España",
      "status": "observado",
      "source_document_id": "doc-avebladder",
      "formula": "229/370 publicado redondeado; diagnóstico 2021–junio 2023",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "avel-cohortshare",
      "entity_type": "rwe",
      "entity_id": "avebladder-229",
      "variable": "Avelumab entre elegibles",
      "value": 37,
      "unit": "%",
      "year": 2023,
      "territory": "14 centros norte España",
      "status": "observado",
      "source_document_id": "doc-avebladder",
      "formula": "85/229 publicado redondeado; no cuota SNS 2025",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "avel-cycles",
      "entity_type": "rwe",
      "entity_id": "avebladder-85",
      "variable": "Mediana ciclos avelumab",
      "value": 7.5,
      "unit": "ciclos",
      "year": 2023,
      "territory": "14 centros norte España",
      "status": "observado",
      "source_document_id": "doc-avebladder",
      "formula": "1–49; no media, censurados incluidos; 800 mg cada 2 semanas",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "bladder-spend-observed",
      "entity_type": "resultado",
      "entity_id": "bladder-2025",
      "variable": "Gasto farmacológico observado atribuible",
      "value": null,
      "unit": "EUR",
      "year": 2025,
      "territory": "España",
      "status": "no_disponible",
      "source_document_id": "doc-sanidad-hosp-2025",
      "formula": "No localizado en fuentes consultadas; ninguna tabla de gasto general discrimina diagnóstico",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "onco-l01-2024",
      "entity_type": "SNS-oncologia",
      "entity_id": "l01-2024",
      "variable": "Consumo hospitalario L01",
      "value": 3462699500,
      "unit": "EUR PVL-deduccion RDL",
      "year": 2024,
      "territory": "Hospitales SNS red pública",
      "status": "observado",
      "source_document_id": "doc-farmacia-2024",
      "formula": "Tabla 24 p62; no vejiga ni suma al proxy",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "onco-l01ff-2024",
      "entity_type": "SNS-oncologia",
      "entity_id": "l01ff-2024",
      "variable": "Consumo PD-1/PD-L1",
      "value": 613774300,
      "unit": "EUR PVL-deduccion RDL",
      "year": 2024,
      "territory": "Hospitales SNS red pública",
      "status": "observado",
      "source_document_id": "doc-farmacia-2024",
      "formula": "Tabla 26 p64; clase multiindicación; 745.800 envases; no avelumab desglosado",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "onco-total-2021",
      "entity_type": "SNS-oncologia",
      "entity_id": "l01l02-2021",
      "variable": "Consumo oncológico hospital+receta",
      "value": 3109920000,
      "unit": "EUR PVL-deduccion RDL",
      "year": 2021,
      "territory": "SNS",
      "status": "observado",
      "source_document_id": "doc-oncologicos-2016-2021",
      "formula": "Tabla 9 p20; hospital 2.898,2M receta 211,72M; no vejiga",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "onco-iqvia-2025",
      "entity_type": "mercado-oncologia",
      "entity_id": "l01l02-2025",
      "variable": "Consumo oncológico contraste",
      "value": 8656076251,
      "unit": "EUR PVL sin descuentos/techos",
      "year": 2025,
      "territory": "EMH/IQVIA cobertura pública declarada",
      "status": "observado",
      "source_document_id": "doc-iqvia-im-2025",
      "formula": "Página 12; contraste secundario, no definición coste real ni C67",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "bladder-aecc-local",
      "entity_type": "coste-vejiga",
      "entity_id": "local-2018",
      "variable": "Coste medio tratamiento local",
      "value": 11820,
      "unit": "EUR/paciente/año",
      "year": 2018,
      "territory": "España, coste sanitario total",
      "status": "estimado",
      "source_document_id": "doc-aecc-coste-2020",
      "formula": "Tabla 4 p13, informe 2020; no exclusivo farmacia, no observado 2025",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "bladder-aecc-met",
      "entity_type": "coste-vejiga",
      "entity_id": "metastatic-2018",
      "variable": "Coste medio tratamiento metastásico",
      "value": 29718,
      "unit": "EUR/paciente/año",
      "year": 2018,
      "territory": "España, coste sanitario total",
      "status": "estimado",
      "source_document_id": "doc-aecc-coste-2020",
      "formula": "Tabla 4 p13, informe 2020; no integrar con PIM ni sustituir supuesto",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "inc-seom-2023",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-2023",
      "variable": "Incidencia SEOM/REDECAN vejiga",
      "value": 21694,
      "unit": "casos",
      "year": 2023,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-avances-vejiga-2025",
      "formula": "Contraste histórico SEOM 2023; no utiliza base 2025",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "inc-seom-2024",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-2024",
      "variable": "Incidencia SEOM/REDECAN vejiga",
      "value": 22097,
      "unit": "casos",
      "year": 2024,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-avances-vejiga-2025",
      "formula": "Contraste histórico SEOM 2024; no utiliza base 2025",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "inc-seom-2026",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-2026",
      "variable": "Incidencia SEOM/REDECAN vejiga",
      "value": 23929,
      "unit": "casos",
      "year": 2026,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-cifras-2026",
      "formula": "Tabla 2 p13; año separado, no proyectar como gasto",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "prev-h-2020",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-hombres-2020",
      "variable": "Prevalencia total a 2020 hombres",
      "value": 149795,
      "unit": "personas",
      "year": 2020,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-cifras-2026",
      "formula": "Figura 9, no avanzados o exposición a fármacos; no reemplaza multiplicador",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "prev-m-2020",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-mujeres-2020",
      "variable": "Prevalencia total a 2020 mujeres",
      "value": 32692,
      "unit": "personas",
      "year": 2020,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-cifras-2026",
      "formula": "Figura 11, no avanzados o exposición a fármacos; no reemplaza multiplicador",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "prev-h5-2020",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-hombres-2020",
      "variable": "Prevalencia 5 años hombres",
      "value": 62462,
      "unit": "personas",
      "year": 2020,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-cifras-2026",
      "formula": "Figura 10, no multiplicar incidencia para estimar avanzados",
      "consulted_at": "2026-11-06"
    },
    {
      "id": "prev-m5-2020",
      "entity_type": "epidemiologia",
      "entity_id": "bladder-mujeres-2020",
      "variable": "Prevalencia 5 años mujeres",
      "value": 14134,
      "unit": "personas",
      "year": 2020,
      "territory": "España",
      "status": "estimado",
      "source_document_id": "doc-seom-cifras-2026",
      "formula": "Figura 12, no multiplicar incidencia para estimar avanzados",
      "consulted_at": "2026-11-06"
    }
  ],
  "meta": {
    "table": "observations",
    "count": 33,
    "limit": 100,
    "model_version": "v5-2026-11-06",
    "scope_note": "Observado general SNS no equivale a atribución vejiga; consultar source_documents vinculados."
  }
}